OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announc …
( read original story …)

---